Medical devices

Medical devices

Medical devices

Until the application of a new regulatory framework for the EU beginning from 26 May 2021, the regulatory framework in the EU for medical devices, active implantable medical devices (AIMDs), and in vitro diagnostic medical devices (IVDs) consisted of:

•
Directive 93/42/EEC on medical devices
•
Directive 90/385/EEC on active implantable medical devices
•
Directive 98/79/EC on in vitro diagnostic medical devices

In the UK, the MD Directives have been implemented via the Medical Devices Regulations 2002, SI 2002/618, which were issued under the Consumer Protection Act 1987. The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK competent authority responsible for supervision of medical device regulation. The end of the Brexit transition period has brought changes to the UK regime.

In the EU, the above directives are replaced by two regulations:

•
Regulation (EU) 2017/745, the Medical Devices Regulation or MDR, which

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

TAKE A FREE TRIAL

Latest Life Sciences News

Main challenges of EU AI Act-GDPR interplay identified by Member States

MLex: Potentially conflicting legal requirements, national governance approaches to ensure regulatory consistency, as well as clear legal advice to minimise the compliance burden, are the main issues seen by EU Member States in the interplay between the EU AI Act and the EU’s General Data Protection Regulation, Regulation (EU) 2016/679 (EU GDPR). European governments have pointed out that the two laws' diverging regulatory approaches might lead to conflicting outcomes, which should be avoided with systematic cooperation between the responsible authorities.

Where there's no waiver, there's no way (Barclays Bank plc v VEB.RF)

Commercial analysis: The English High Court has provided further guidance on the interpretation of ‘no waiver’ clauses in a recent decision. The backdrop to this decision was a sanctions related dispute about the termination of a currency swap agreement between two banks, one of which was Russian, the other English. The agreement had a dispute resolution clause where the forum was arbitration unless the English bank gave notice that a dispute should be heard by the English courts. Pamela Vassil, lawyer at A&O Shearman, examines the court’s decision.

HRA publishes updated health and social care research model agreements

The Health Research Authority (HRA) has published updates to its Model Commercial Chief Investigator Agreement (mCCIA) and Model Confidential Disclosure Agreements (mCDAs). These model agreements are used in health and social care research throughout the UK and must be used from 28 April 2025. These amends form part of the HRA's UK Clinical Research Delivery programme which aims to develop and mandate an efficient and streamlined single UK standardised commercial contracting process to reduce unnecessary negotiation. The HRA now aims to update the model commercial site agreements for publication in May 2025.

What do legal teams need to know about AI standards?

TMT analysis: This analysis considers the role of technical standards in the ICT sector and in particular in relation to artificial intelligence (AI). It discusses some of the standards that have been developed relevant to AI, the project to create standards under the EU AI Act and the UK government’s approach. It also considers how standards can be leveraged by customers procuring AI systems, both internally and in contract negotiations. Written by Dr Sam De Silva, partner and global co-head of the Commercial Practice Group, CMS Cameron McKenna Nabarro Olswang LLP.